AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Radiopharm's 15min chart triggers Bollinger Bands Narrowing, KDJ Death Cross formation.
ByAinvest
Tuesday, Aug 5, 2025 1:18 pm ET1min read
Based on the 15-minute chart for Radiopharm, the narrowing of Bollinger Bands and the KDJ Death Cross observed on August 5, 2025 at 13:15 indicates a decrease in the magnitude of stock price fluctuations and a shift in momentum towards the downside, potentially leading to further declines in the stock price.
Gossamer Bio, Inc. (GOSS), a clinical-stage biopharmaceutical company, recently reported its second quarter 2025 financial results and provided updates on its lead drug candidate, seralutinib. The company completed enrollment of 390 patients in its Phase 3 PROSERA study for the treatment of pulmonary arterial hypertension (PAH), with topline results expected in February 2026. The study's primary endpoint is the change in six-minute walk distance at week 24.Financial highlights for Q2 2025 include $212.9 million in cash and equivalents, expected to fund operations into 2027. The company reported Q2 revenue of $11.5 million, with a net loss of $38.3 million ($0.17 per share). The company is also preparing to launch the Phase 3 SERANATA study for pulmonary hypertension associated with interstitial lung disease (PH-ILD) in Q4 2025, targeting approximately 480 patients.
Gossamer Bio is a late-stage biopharmaceutical company developing seralutinib for the treatment of PAH and PH-ILD. The company's lead candidate, seralutinib, is advancing with the PROSERA Phase 3 trial in PAH, with topline data expected in Q4 2025. The company has also received Orphan Drug Designation in Japan for PAH treatment and plans to initiate a registrational Phase 3 trial for PH-ILD in H2 2025.
The company's stock price has been volatile, with a narrowing of Bollinger Bands and a KDJ Death Cross observed on August 5, 2025 at 13:15, indicating a decrease in the magnitude of stock price fluctuations and a shift in momentum towards the downside, potentially leading to further declines in the stock price.
Gossamer Bio is a promising biopharmaceutical company with a strong pipeline of drug candidates targeting complex conditions. However, investors should closely monitor the company's financial results and clinical trial data to make informed investment decisions.
References:
[1] https://www.stocktitan.net/news/GOSS/
[2] https://www.stocktitan.net/news/GOSS/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet